公开(公告)号：US20180243284A1

公开(公告)日：2018-08-30

申请号：US15758582

申请日：2016-09-09

Applicant: UNIVERSITY OF YAMANASHI ,  TOKAI UNIVERSITY EDUCATIONAL SYSTEM

Inventor： Kanji SUGITA ,  Kiyoshi ANDO

IPC: A61K31/454 ,  A61K31/506

CPC classification number: A61K31/454 ,  A61K31/122 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/553 ,  A61K45/00

Abstract: According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.